Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplaston A10 and AS2-1 in Refractory Stage IV Prostate Cancer
NCT00003534Phase 2Withdrawn
- Sponsor
- Burzynski Research Institute
- Start
- Oct 1996
- Primary completion
- Feb 1997
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in prostate cancer (PCa), sponsored by Burzynski Research Institute. Primary endpoints: Objective Response Rate at 12 months and Safety and Tolerance at 12 months. Planned start Oct 1996; status: withdrawn.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00003534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003534.